Managing glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors in clinical practice heart.bmj.com/content/early/…

Phase 3 trial just published in NEJM for #orforglipron, an oral GLP-1 medication for obesity. At the highest dose, participants saw an average 11.2% weight loss, with 36% losing at least 15% and 18% losing at least 20% of their body weight. Cardiometabolic markers also improved.

Viewpoint discusses the use of #GLP-1 receptor agonists as a strategy to manage psychotropic-induced weight gain and how psychiatric guidelines should consider them for managing pharmacological weight gain in high-risk patients. ja.ma/47WMHKm

📢New online event 📍Join us on 21 October 2025, 7-8 pm to hear collegues and friends celebrate the achievements of Professor John Lazarus in the field of thyroidology. 🔗Register free-of-charge btf-thyroid.org/Event/tribute-… #thyroid #endocrinology

UK Iodine status is precarious, declining and likely having a detrimental effect on brain development (thread) National data show UK women of reproductive age have iodine levels among the lowest in the world. Levels have declined about 25-29% in the last 10 years.

New—Safeguarding natural intelligence: the case for renewed action on iodine sufficiency in the UK thelancet.com/journals/landi… #iodine deficiency #thyroid #IQ #FREE to read

UTI is uncommon with SGLT2i - mycotic infections are common This study has important clinical implications ⚠️ After UTI, 1 in 3 patients stopped SGLT2i Discontinuation led to higher CV & renal risk, with no reduction in recurrent UTIs. 💡 Following UTI - continue SGLT2i

GLP-1 therapies like Ozempic, Wegovy, Mounjaro, and Zepbound are not “prescribe and see you in six months” medications. They require close follow-up, guidance, and consistent support. Education Before prescribing, patient education is critical. Understand the patient’s

My piece in bylines. Iodine, UK policy and brain growth: a question of intelligence. Grateful if people could amplify this ⁦Society for Endo⁩ ⁦Endocrine Society⁩ ⁦BTF Thyroid⁩ ⁦BritishThyroidAssociation⁩ ⁦Thyroid UK⁩ ⁦ centralbylines.co.uk/news/health/io…

Continuous glucose monitoring (CGM) enables real-time assessment of glucose trends in individuals with type 2 #diabetes, complementing or replacing fingerstick and HbA1c monitoring. 💡 This JAMA Insights discusses CGM use for type 2 diabetes. ja.ma/48d0Stj

What is the risk of pancreatitis and gallstones in those taking GLP1 medicines? 🤨 GLP-1RA had no increased risk for pancreatitis compared with SGLT2i initiators (HR 1.01). GLP-1RA showed a modestly increased risk of biliary disease compared with SGLT2i initiators (HR 1.15),

A reminder that MODY (and type 1 diabetes) can present in older individuals and must remain in the differential diagnosis for new onset #diabetes across the lifespan diabetesjournals.org/diabetes/artic…

On Sunday, we want to send our best wishes to our #4, six foot two, eyes of blue, King Billy, the one and only Billy Bonds. From the fourth minute, and as long as we can, let "Billy Bonds Claret and Blue Army" ring out around the London Stadium. #COYI #WHUFC #WHULIV

📉 Our comprehensive review of Medication Adherence published in Diabetologia Non-adherence affects ~38% of people T2 diabetes, Leads to higher HbA1c, more micro/macrovascular complications, hospitalisations, mortality, and major healthcare costs. 🔍 Causes span patient,

Normalization of glucose in people with prediabetes, i.e. achieving remission, is linked to halving of major cardiovascular adverse events over ensuing decades thelancet.com/journals/landi…

Taking the Wegovy pill exactly as directed is extremely important. If patients shortcut the instructions, they dramatically blunt absorption and lose the benefit of the drug. When the tablet is taken after an overnight fast with only a small volume of plain water and no other

New content online: The public health burden of diabetes mellitus and thyroid disease: twin epidemics dlvr.it/TQDPQH

The MHRAgovuk has published a Drug Safety Update for Rybelsus ®. The update advises of the transition to a new formulation and risk of medication error. Further information and advice for healthcare professionals is available on the update ▶️ ow.ly/mqNt50XVBRL

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. bit.ly/4tflPgN

Type 1 #diabetes occurs when the immune system destroys #insulin-producing cells in the pancreas, leading to high blood glucose levels. 📄 Learn more in this JAMA Patient Page: ja.ma/4rjsEMR